Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
$37.20
$1.36(2.35%)
At close: 4:00 PM EST
$37.20
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$29.24 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)845.02K
Market Cap
$1.83B
Enterprise Value$2.13B
Total Cash (Recent Filing)$116.88M
Total Debt (Recent Filing)$101.54M
Price to Earnings (P/E)290.7
Beta1.21
Next Earnings
Feb 26, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding50,460,205
10 Day Avg. Volume667,266
30 Day Avg. Volume845,017
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda131.44
Forecast
1Y Price Target
$50.50Price Target Upside35.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product AdoptionMACI Arthro is expected to play a key role in accelerating Vericel Corporation's top-line growth.
Revenue GrowthBiopsy pipelines, MACI Arthro training momentum, and a 30% salesforce expansion ahead of peak volumes support our call that the company can hit its low-20% MACI revenue growth target in 2025.
Surgeon EngagementThe first commercial year of MACI Arthro is showing robust surgeon engagement and biopsy volume.
Bears Say
Growth ExpectationsSurvey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch, indicating results are likely to be in-line to slightly lower than Street estimates.
Market UncertaintyShares trade at around 5x NTM EV/Sales with much of the weakness priced in, but without expected upside, uncertainty remains on what could reignite investor interest.
Stock PerformanceVCEL shares are down approximately 42% year-to-date following two softer quarters, indicating performance challenges.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $29.24 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.83B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Feb 26, 2026 which is in 112 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.006 by $0.106.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.39.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,460,205 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.006. Following the earnings report the stock price went down -14.068%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.50 (35.75% Upside)
$50.50 (35.75% Upside)
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.15%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vericel's strong financial performance with record revenue and profit growth, driven by the success of MACI and the launch of MACI Arthro. However, there are potential challenges related to government processes and reimbursement policies that could impact future growth.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$50.50
▲(35.75% Upside)
Technical Analysis
Ownership Overview
1.06% Insiders
39.00% Mutual Funds
3.35% Other Institutional Investors
34.27% Public Companies and
Individual Investors